InvestorsObserver
×
News Home

What is the Market's View on Zynerba Pharmaceuticals Inc (ZYNE) Stock's Price and Volume Trends Monday?

Monday, October 02, 2023 12:25 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Zynerba Pharmaceuticals Inc (ZYNE) Stock's Price and Volume Trends Monday?

Zynerba Pharmaceuticals Inc (ZYNE) stock is lower by 3.79% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bearish
Zynerba Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ZYNE!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ZYNE Stock Today?

Zynerba Pharmaceuticals Inc (ZYNE) stock is unchanged -0.39% while the S&P 500 is down -0.38% as of 11:53 AM on Monday, Oct 2. ZYNE is unmoved $0.00 from the previous closing price of $1.27 on volume of 284,330 shares. Over the past year the S&P 500 is up 16.13% while ZYNE has risen 62.82%. ZYNE lost -$0.80 per share in the over the last 12 months.

More About Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. Click Here to get the full Stock Report for Zynerba Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App